Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

NCT07581834 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT07581834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07581834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 21, 2026
Completion date
June 30, 2032
Enrollment
2,000 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast diseases, breast neoplasms, cdk4/6 inhibitor, dalpiciclib, endocrine breast diseases, hr+/her2- breast cancer